Shi Han Wei
Direktor/Vorstandsmitglied bei Beijing Xiangxin Biotechnology Co., Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Lei Lin | M | 57 |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | 4 Jahre |
Lan Hu | M | 55 |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | 5 Jahre |
Rui Lin | F | 53 |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | 4 Jahre |
Hua Liu | M | 45 |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | - |
Zhi Xing Chen | M | - |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | 6 Jahre |
Si Ying Ma | M | - |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | 4 Jahre |
Shan Bai Cao | M | - |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | - |
Feng Lou | M | - |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | - |
Jia Jia Duan | F | - |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | 5 Jahre |
Bin Dong | M | - |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | - |
Rui Zhao | F | - |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | - |
Yi Li Zhao | M | - |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | - |
Qiu Bo Sun | M | - |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | - |
Jing Guo | M | - |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | - |
Xiao Peng Ma | M | - |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | 6 Jahre |
Ying Hui He | M | - |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
China | 16 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Shi Han Wei
- Persönliches Netzwerk